血脂康对合并高血压患者的冠心病二级预防作用

目的探讨血脂康在合并高血压患者中的冠心病二级预防效果。方法对一项随机、双盲、安慰剂对照试验中的2704例合并高血压、2166例不合并高血压的冠心病患者的干预结果进行分析,并对高血压患者按照脉压分组进行统计。结果冠心病合并高血压患者的冠心病事件的发生率和总死亡率明显高于不合并高血压的患者。在合并高血压患者中,高脉压组（脉压〉50mmHg,1mmHg=0．133kPa）患者的死亡率和脑卒中发生率明显高于低脉压组（脉压≤50mmHg）患者。与对照组比较,冠心病事件和总死亡率在合并高血压患者中分别降低44．0％（P〈0．0001）和35．8％（P=0．0012）,在不合并高血压患者中分别降低47．4％（P〈0．0001）和28．6％（P=0．0737）。在全部合并高血压的患者中,肿瘤死亡减少67．5％（P=0．0071）。在低脉压组患者中,肿瘤事件减少62．6％（P=0．0399）。没有发现治疗组临床不良反应或实验室安全指标的增加。结论对冠心病合并高血压的患者应积极进行调脂治疗,血脂康用于高血压患者的冠心病二级预防是安全有效的。

The beneficial effects of lipid-lowering therapy with xuezhikang on cardiac events and total mortality in coronary heart disease patients with or without hypertension: a random, double-blinded, placebo controlled clinical trial

Objective To evaluate whether lipid-lowering therapy with Xuezhikang can reduce the risk of cardiac events and total mortality in coronary heart disease(CHD)patients with or without hypertension.Methods In this random,double-blinded,placebo controlled clinical trial,2704 patients with hypertension and 2166 patients without hypertension were enrolled and capsule Xuezhikang 0.6 g Bid or placebo on the top of conventional therapy without other lipid-lowering drugs.The mean follow-up period was four years.The primary end-points were nonfatal myocardial infarction and total mortality.Results Compared to placebo group,the incidence of cardiac events was reduced by 44.0%(P<0.0001)and 47.4%(P<0.0001)respectively in CHD patients with or without hypertension,and the total mortality was lowered by 35.8%(P=0.0012)and 28.6%(P=0.0737)respectively in CHD patients with or without hypertension.There was no significant difference in side effects between study groups. Conclusion Xuezbikang can reduce the cardiac events and mortality in CHD patients with or without hypertension.